Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Semin Cancer Biol. 2022 Oct;85:123-154. doi: 10.1016/j.semcancer.2021.05.010. Epub 2021 May 13.
The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway involved in cell proliferation and survival. The three-layered MAPK signaling cascade is initiated upon RTK and RAS activation. Three RAF isoforms ARAF, BRAF and CRAF, and their downstream MEK1/2 and ERK1/2 kinases constitute a coherently orchestrated signaling module that directs a range of physiological functions. Genetic alterations in this pathway are among the most prevalent in human cancers, which consist of numerous hot-spot mutations such as BRAF. Oncogenic mutations in this pathway often override otherwise tightly regulated checkpoints to open the door for uncontrolled cell growth and neoplasia. The crosstalk between the RAF-MEK-ERK axis and other signaling pathways further extends the proliferative potential of this pathway in human cancers. In this review, we summarize the molecular architecture and physiological functions of the RAF-MEK-ERK pathway with emphasis on its dysregulations in human cancers, as well as the efforts made to target the RAF-MEK-ERK module using small molecule inhibitors.
RAF-MEK-ERK 信号级联是一个特征明确的 MAPK 通路,参与细胞增殖和存活。该三层 MAPK 信号级联在 RTK 和 RAS 激活时启动。三种 RAF 同工型(ARAF、BRAF 和 CRAF)及其下游 MEK1/2 和 ERK1/2 激酶构成了一个协调一致的信号模块,指导着多种生理功能。该通路中的遗传改变是人类癌症中最常见的改变之一,其中包括许多热点突变,如 BRAF。该通路中的致癌突变通常会绕过其他严格调控的检查点,为不受控制的细胞生长和肿瘤形成打开大门。RAF-MEK-ERK 轴与其他信号通路的串扰进一步扩展了该通路在人类癌症中的增殖潜力。在这篇综述中,我们总结了 RAF-MEK-ERK 通路的分子结构和生理功能,重点介绍了其在人类癌症中的失调,以及使用小分子抑制剂靶向 RAF-MEK-ERK 模块所做的努力。
Semin Cancer Biol. 2022-10
Sci Signal. 2011-3-29
Proc Natl Acad Sci U S A. 2010-7-28
Expert Rev Mol Med. 2012-10-12
Biochim Biophys Acta. 2007-8
Blood Lymphat Cancer. 2025-8-18
Cancers (Basel). 2025-7-4